Sep 24, 2026 8:00am EDT Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
Sep 15, 2026 9:15am EDT Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
Sep 14, 2026 8:00am EDT Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
Sep 02, 2026 8:30am EDT Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
Aug 20, 2026 8:00am EDT Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
Aug 13, 2026 4:15pm EDT Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 06, 2026 8:00am EDT Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Jul 14, 2026 8:00am EDT Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Jun 26, 2026 8:00am EDT Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study